CI

At a glance

ClinicalIndex Comparison Record
Phase 1Completed· 198 enrolled
Drug / intervention
MLN0128drug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01058707
NCT01058707Phase 1Completed
CompareCT.gov

A Phase I, Open Label, Dose Escalation Study of Oral Administration of Single Agent INK128 in Subjects With Advanced Malignancies Followed by an Expansion in Subjects With Measurable Disease

Millennium Pharmaceuticals, Inc.·interventional·Posted Jan 29, 2010·Updated Apr 1, 2020

In Brief

A Phase 1 clinical trial evaluating MLN0128 for Advanced Solid Malignancies. Completed, enrolled 198 participants across 16 sites in 2 countries.

Detailed Summary

This is a Phase I, open label, Dose Escalation study of oral administration of single agent MLN0128 in participants with Advanced Malignancies followed by an Expansion Phase in participants with renal cell carcinoma, endometrial cancer or urothelial cancer who have measurable disease.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAdvanced Solid Malignancies
CountriesSpain, United States
Collaborators--

Timeline

Phase 1CompletedFinished
20102011201220132014201520162017201820192020202120222023202420252026
First PostedJan 29, 2010
Enrollment StartJan 4, 2010
Primary CompletionFeb 7, 2019
TodayJul 2, 2026
Enrollment to primary: 9.1 yearsPosted 16.4 years ago

Interventions

MLN0128drug

MLN0128 capsules